ArticlePsychological medicine2015
Substance use in individuals at clinical high risk of psychosis.
Article in Psychological medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review.Social psychiatry and psychiatric epidemiology · 2020Pooled it
- Cannabis use and symptom severity in individuals at ultra high risk for psychosis: a meta-analysis.Acta psychiatrica Scandinavica · 2017Pooled it
- Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.Schizophrenia research · 2023Trial
- Sociodemographic influences on substance use in psychosis in an African cohort.Schizophrenia research · 2025Article
- PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample.Schizophrenia (Heidelberg, Germany) · 2025Article
- Physical Health and Transition to Psychosis in People at Clinical High Risk.Biomedicines · 2024Article
- Influence of cannabis use on incidence of psychosis in people at clinical high risk.Psychiatry and clinical neurosciences · 2023Article
- The impact of early factors on persistent negative symptoms in youth at clinical high risk for psychosis.Frontiers in psychiatry · 2023Article
- Review
- Longitudinal and cross-sectional validation of the WERCAP screen for assessing psychosis risk and conversion.Schizophrenia research · 2022Article
- Telepsychotherapy with Youth at Clinical High Risk for Psychosis: Clinical Issues and Best Practices during the COVID-19 Pandemic.Journal of psychotherapy integration · 2020Article
- What prevents youth at clinical high risk for psychosis from engaging in physical activity? An examination of the barriers to physical activity.Schizophrenia research · 2018Article
- y-QUIT: Smoking Prevalence, Engagement, and Effectiveness of an Individualized Smoking Cessation Intervention in Youth With Severe Mental Illness.Frontiers in psychiatry · 2018Article
- Evidence of a Causal Relationship Between Smoking Tobacco and Schizophrenia Spectrum Disorders.Frontiers in psychiatry · 2018Review
- The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.Psychoneuroendocrinology · 2017Article
- The Role of Trauma and Stressful Life Events among Individuals at Clinical High Risk for Psychosis: A Review.Frontiers in psychiatry · 2017Review
- Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis.Psychiatry research. Neuroimaging · 2016Article
- Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis.Psychiatry research · 2015Article
- Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis.BMC psychiatry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundA series of research reports has indicated that the use of substances such as cannabis, alcohol and tobacco are higher in youth at clinical high risk (CHR) of developing psychosis than in controls. Little is known about the longitudinal trajectory of substance use, and findings on the relationship between substance use and later transition to psychosis in CHR individuals are mixed.
methodAt baseline and 6- and 12-month follow-ups, 735 CHR and 278 control participants completed the Alcohol and Drug Use Scale and a cannabis use questionnaire. The longitudinal trajectory of substance use was evaluated with linear mixed models.
resultsCHR participants endorsed significantly higher cannabis and tobacco use severity, and lower alcohol use severity, at baseline and over a 1-year period compared with controls. CHR youth had higher lifetime prevalence and frequency of cannabis, and were significantly younger upon first use, and were more likely to use alone and during the day. Baseline substance use did not differentiate participants who later transitioned to psychosis (n = 90) from those who did not transition (n = 272). Controls had lower tobacco use than CHR participants with a prodromal progression clinical outcome and lower cannabis use than those with a psychotic clinical outcome at the 2-year assessment.
conclusionsIn CHR individuals cannabis and tobacco use is higher than in controls and this pattern persists across 1 year. Evaluation of clinical outcome may provide additional information on the longitudinal impact of substance use that cannot be detected through evaluation of transition/non-transition to psychosis alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.